Mutation Rate of AmpC β-Lactamase–Producing Enterobacterales and Treatment in Clinical Practice: A Word of Caution-Reference-Cited by-同舟云学术

Mutation Rate of AmpC β-Lactamase–Producing Enterobacterales and Treatment in Clinical Practice: A Word of Caution

Published:2024-03-25 Issue:1 Volume:79 Page:52-55
ISSN:1058-4838
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:

Author:

Maillard Alexis¹^ORCID,Dortet Laurent²³⁴,Delory Tristan⁵,Lafaurie Matthieu⁶,Bleibtreu Alexandre¹⁷, ,Azoulay Elie,Joseph Adrien,Molina Jean-Michel,Lafaurie Matthieu,Bercot Béatrice,Maillard Alexis,Paccoud Olivier,Bleibtreu Alexandre,Robert Jérôme,Drieux Laurence,Bernier Juliette,Villa Antoine,Maury Éric,Surgers Laure,Chopin Dorothée,Lalande Valérie,Tankovic Jacques,Delory Tristan,Contejean Adrien,Poupet Hélène,Mouthon Luc,Baillard Christophe,Escaut Lélia,Jaureguiberry Stéphane,Cuzon Gaëlle,Dortet Laurent,Chaibi Khalil,El Alaoui Fatma,Zahar Jean-Ralph

Affiliation:

1. Department of Infectious Diseases, Pitié-Salpêtrière Hospital, Assistance Publique–Hôpitaux de Paris (AP-HP) and Sorbonne Université , Paris , France

2. Department of Bacteriology-Hygiene, Bicêtre Hospital, AP-HP , Le Kremlin-Bicêtre , France

3. Faculty of Medicine, UMR-1184, Inserm, University Paris-Saclay , Le Kremlin-Bicêtre , France

4. French National Reference Center for Antimicrobial Resistance , Le Kremlin-Bicêtre , France

5. Clinical Research Unit, Annecy-Genevois Hospital , Epagny-Metz-Tessy , France

6. Department of Infectious Diseases, Saint-Louis Hospital, AP-HP , Paris , France

7. Inserm U1135, Cimi-Paris , Paris , France

Abstract

Abstract In a retrospective multicenter study of 575 patients with bloodstream infections or pneumonia due to wild-type AmpC β-lactamase–producing Enterobacterales, species with low in vitro mutation rates for AmpC derepression were associated with fewer treatment failures due to AmpC overproduction (adjusted hazard ratio, 0.5 [95% CI, .2–.9]). However, compared to cefepime/carbapenems, using third-generation cephalosporins as definitive therapy remained associated with this adverse outcome (15% vs 1%).

Publisher

Oxford University Press (OUP)

Link

https://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciae160/57505902/ciae160.pdf

Reference12 articles.

1. A primer on AmpC β-lactamases: necessary knowledge for an increasingly multidrug-resistant world;Tamma;Clin Infect Dis,2019

2. Infections caused by naturally AmpC-producing Enterobacteriaceae: can we use third-generation cephalosporins? A narrative review;Mizrahi;Int J Antimicrob Agents,2020

3. Piperacillin-tazobactam should be preferred to third-generation cephalosporins to treat wild-type inducible AmpC-producing Enterobacterales in critically ill patients with hospital or ventilator-acquired pneumonia;Carrié;J Crit Care,2020

4. Antibiotic definitive treatment in ventilator associated pneumonia caused by AmpC-producing Enterobacterales in critically ill patients: a prospective multicenter observational study;Petit;Crit Care,2024

5. Species-specific mutation rates for ampC derepression in Enterobacterales with chromosomally encoded inducible AmpC β-lactamase;Kohlmann;J Antimicrob Chemother,2018

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Outcomes of Patients with AmpC-Beta-Lactamase-Producing Enterobacterales Bacteremia Treated with Carbapenems versus Non-Carbapenem Regimens: A Single-Center Study;Antibiotics;2024-07-29